Chart: Five Steps To A Less Risky FDA: PDUFA's 2008-2012 Safety Plan
You may also be interested in...
FDA’s 5-Year Plan For User Fees Puts Post- And Pre-Market On Equal Footing
Over the next five years, FDA will shift its regulatory focus to ensure that the safe and effective use of drugs is of equal importance as ushering safe and effective medicines to market
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials